Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Expands By 22.9%

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 986,300 shares, an increase of 22.9% from the November 30th total of 802,800 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average trading volume of 525,700 shares, the days-to-cover ratio is currently 1.9 days.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in shares of Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after buying an additional 25,300 shares during the last quarter. Ally Bridge Group NY LLC lifted its holdings in Context Therapeutics by 159.8% during the second quarter. Ally Bridge Group NY LLC now owns 1,886,232 shares of the company’s stock worth $3,782,000 after acquiring an additional 1,160,281 shares during the period. Great Point Partners LLC purchased a new position in Context Therapeutics in the second quarter worth $14,876,000. Affinity Asset Advisors LLC grew its stake in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,290,323 shares during the period. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of Context Therapeutics during the 2nd quarter valued at $10,348,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd. D. Boral Capital assumed coverage on Context Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $9.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $6.80.

Context Therapeutics Trading Down 0.5 %

NASDAQ CNTX traded down $0.01 during trading hours on Tuesday, hitting $1.06. The company’s stock had a trading volume of 1,433,842 shares, compared to its average volume of 363,410. The company has a market capitalization of $79.12 million, a PE ratio of -1.16 and a beta of 2.00. Context Therapeutics has a 52 week low of $0.89 and a 52 week high of $2.75. The company’s 50-day simple moving average is $1.67 and its two-hundred day simple moving average is $1.98.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.